Effects of Intracoronary Infusion of Escalating Doses of Cardiac Stem Cells in Rats With Acute Myocardial Infarction

Tang, Xian-Liang; Rokosh, Gregg; Sanganalmath, Santosh K.; Tokita, Yukichi; Keith, Matthew C. L.; Shirk, Gregg; Stowers, Heather; Hunt, Gregory N.; Wu, Wenjian; Dawn, Buddhadeb; Bolli, Roberto

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Effects of Intracoronary Infusion of Escalating Doses of Cardiac Stem Cells in Rats With Acute Myocardial Infarction

Published Date:

May 20 2015

Source:

Circ Heart Fail. 8(4):757-765.

Language:

English

[PDF-2.98 MB]

Details:

Personal Authors:

Tang, Xian-Liang ; Rokosh, Gregg ; Sanganalmath, Santosh K. ; Tokita, Yukichi ; Keith, Matthew C. L. ; ... More ▼

Keywords:

[+]

Pubmed ID:

25995227

Pubmed Central ID:

PMC4512882

Description:

Background

Although c-kitpos cardiac stem cells (CSCs) preserve left ventricular (LV) function and structure after myocardial infarction (MI), CSC doses have been chosen arbitrarily and the dose-effect relationship is unknown.

Methods and Results

Rats underwent a 90-min coronary occlusion followed by 35 days of reperfusion. Vehicle or CSCs at 5 escalating doses (0.3 ×106, 0.75 ×106, 1.5 ×106, 3.0 ×106, and 6.0 ×106 cells/heart) were given intracoronarily 4 h after reperfusion. The lowest dose (0.3 ×106) had no effect on LV function and morphology, whereas 0.75, 1.5, and 3.0 ×106 significantly improved regional and global LV function (echocardiography and hemodynamic studies). These three doses had similar effects on echocardiographic parameters (infarct wall thickening fraction, LV end-systolic and end-diastolic volumes, LV ejection fraction) and hemodynamic variables (LV end-diastolic pressure, LV dP/dtmax, preload adjusted maximal power, end-systolic elastance, preload recruitable stroke work), and produced similar reductions in apoptosis, scar size, infarct wall thinning, and LV expansion index and similar increases in viable myocardium in the risk region (morphometry). Infusion of 6.0 ×106 CSCs markedly increased post-procedural mortality. GFP and BrdU staining indicated that persistence of donor cells and formation of new myocytes were negligible with all doses.

Conclusions

Surprisingly, in this rat model of acute MI, the dose-response relationship for intracoronary CSCs is flat. A minimal dose between 0.3 and 0.75 ×106 is necessary for efficacy; above this threshold, a four-fold increase in cell number does not produce greater improvement in LV function or structure. Further increases in cell dose are harmful.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

R01 HL055757/HL/NHLBI NIH HHS/United States
R01-HL74351/HL/NHLBI NIH HHS/United States
1 UM1 HL-113530/HL/NHLBI NIH HHS/United States
H75 DP424252/DP/NCCDPHP CDC HHS/United States
P01 HL078825/HL/NHLBI NIH HHS/United States
R01 HL074351/HL/NHLBI NIH HHS/United States
UM1 HL113530/HL/NHLBI NIH HHS/United States
P01-HL78825/HL/NHLBI NIH HHS/United States
R01 HL068088/HL/NHLBI NIH HHS/United States

Supporting Files:

	nihms693682f3.gif	image/gif
	nihms693682f3.jpg	image/jpeg
	nihms693682f4.gif	image/gif
	nihms693682f4.jpg	image/jpeg
	nihms693682f5.gif	image/gif
	nihms693682f5.jpg	image/jpeg
	nihms693682f6.gif	image/gif
	nihms693682f6.jpg	image/jpeg
	nihms693682f7.gif	image/gif
	nihms693682f7.jpg	image/jpeg
	NIHMS693682-supplement-CircHF_CIRCHF-2015-002210_xml.xml	application/xml
	nihms693682f8.gif	image/gif
	nihms693682f8.jpg	image/jpeg
	NIHMS693682-supplement-Clinical_Perspective.docx	application/vnd.openxmlformats-officedocument.wordprocessingml.document
	NIHMS693682-supplement-Supplemental_Material.pdf	application/pdf
	nihms693682.nxml	text/xml
	nihms693682f1.gif	image/gif
	nihms693682f1.jpg	image/jpeg
	nihms693682f2.gif	image/gif
	nihms693682f2.jpg	image/jpeg

No Related Documents.

You May Also Like:

Repeated Administrations of Cardiac Progenitor Cells Are Markedly More Effective Than a Single Administration: A New Paradigm in Cell Therapy

Personal Author:

Tokita, Yukichi; Tang, Xian-Liang; Li, Qianhong; Wysoczynski, Marcin; Hong, Kyung U; Bolli, Roberto A.; Nakamura, Shunichi; Wu, Wen-Jian; Xie, Wei; Li, Ding; Hunt, Greg; Ou, Qinghui; Stowers, Heather; Bolli, Roberto;

Published:

Jun 30 2016

Source:

Circ Res. 119(5):635-651.

Description:

Rationale : The effects of c-kitPOS cardiac progenitor cells (CPCs) (and adult cell therapy in general) on left ventricular (LV) function have been regarded as modest or inconsistent. : Objective : To determine whether three CPC infusions have greate...

File Type:

[PDF - 4.95 MB]
Long-Term Outcome of Administration of c-kitPOS Cardiac Progenitor Cells After Acute Myocardial Infarction: Transplanted Cells Do Not Become Cardiomyocytes, Structural and Functional Improvement and Proliferation of Endogenous Cells Persist for at Least One Year

Personal Author:

Tang, Xian-Liang; Li, Qianhong; Rokosh, Gregg; Sanganalmath, Santosh K.; Chen, Ning; Ou, Qinghui; Stowers, Heather; Hunt, Greg; Bolli, Roberto;

Published:

Feb 02 2016

Source:

Circ Res. 118(7):1091-1105.

Description:

RATIONALE : Cardiac progenitor cells (CPCs) improve left ventricular (LV) remodeling and function after acute or chronic myocardial infarction (MI). However, the long-term (>5 weeks) effects, potential tumorigenicity, and fate of transplanted CPCs ar...

File Type:

[PDF - 4.35 MB]
Arrhythmia in Stem Cell Transplantation

Personal Author:

Almeida, Shone O.; Skelton, Rhys J.; Adigopula, Sasikanth; Ardehali, Reza;

Published:

Apr 09 2015

Source:

Card Electrophysiol Clin. 2015; 7(2):357-370.

Description:

Stem cell regenerative therapies hold promise for treating diseases across the spectrum of medicine. While significant progress has been made in the preclinical stages, the clinical application of cardiac cell therapy is limited by technical challeng...

File Type:

[PDF - 702.10 KB]
Potential Strategies for Clinical Translation of Repeated Cell Therapy

Personal Author:

Vrtovec, Bojan; Bolli, Roberto;

Published:

Mar 2019

Source:

Circ Res. 124(5):690-692

Public Access
Available on:

March 01, 2020
Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance

Personal Author:

Vasu, Sujethra; Bandettini, W Patricia; Hsu, Li-Yueh; Kellman, Peter; Leung, Steve; Mancini, Christine; Shanbhag, Sujata M; Wilson, Joel; Booker, Oscar Julian; Arai, Andrew E;

Published:

Sep 24 2013

Source:

J Cardiovasc Magn Reson. 2013; 15(1):85.

Description:

Background : Regadenoson, dipyridamole and adenosine are commonly used vasodilators in myocardial perfusion imaging for the detection of obstructive coronary artery disease. There are few comparative studies of the vasodilator properties of regadenos...

File Type:

[PDF - 1.22 MB]